SCHEMBL7783922

SCHEMBL7783922

Cc1cc(C(=O)Cl)ccc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.60
RXRA P19793 1/20 0.58
RXRB P28702 1/20 0.58
RXRG P48443 1/20 0.58
MRGPRX4 Q96LA9 7/20 0.56
GLRA1 P23415 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
SMPD1 P17405 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
FFAR1 O14842 2/20 0.50
PTGER1 P34995 1/20 0.48
MCL1 Q07820 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71526 0.88 RXRA (0.58) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL13440174 0.88 RXRA (0.70) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL385027 0.87 FFAR4 (0.62) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL29783148 0.87 FFAR4 (0.62) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL1599431 0.86 HPGD (0.59) RXRARXRBMRGPRX4GLRA1SMN1; SMN2
SCHEMBL29557477 0.86 HPGD (0.59) RXRARXRBMRGPRX4GLRA1SMN1; SMN2
SCHEMBL6356140 0.84 GLRA1 (0.56) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL23226754 0.84 FFAR4 (0.59) FFAR4RXRARXRBRXRGMRGPRX4
SCHEMBL341137 0.84 NPC1 (0.73) RXRAMRGPRX4SMN1; SMN2NPC1HPGD
SCHEMBL20059720 0.84 LMNA (0.59) FFAR4RXRARXRBRXRGMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056575-A1 Anesthetic Compounds SIGNATURE THERAPEUTICS, INC. 2010-03-04 US disclosed
EP-0687288-B1 MANNICH CONDENSATION PRODUCTS OF POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME CHEVRON CHEM CO (US) 2001-11-21 EP disclosed
EP-0636164-B1 POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME CHEVRON CHEM CO (US) 2000-05-24 EP disclosed
EP-0626994-B1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES CHEVRON CHEM CO (US) 2000-03-01 EP disclosed
EP-0629232-B1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES CHEVRON CHEM CO (US) 1999-09-15 EP disclosed
EP-0687288-A4 MANNICH CONDENSATION PRODUCTS OF POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME CHEVRON CHEM CO (US) 1996-05-08 EP disclosed
US-5482522-A ESTERIFIED ENDCAPPED POLYETHERS, ANTIDEPOSIT AGENTS CHEVRON CHEMICAL COMPANY (US) 1996-01-09 US disclosed
EP-0687288-A1 MANNICH CONDENSATION PRODUCTS OF POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME CHEVRON CHEMICAL COMPANY (US) 1995-12-20 EP disclosed
US-5462567-A Antideposit agents CHEVRON CHEMICAL COMPANY (US) 1995-10-31 US disclosed
EP-0629232-A4 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES. CHEVRON RES & TECH (US) 1995-08-23 EP disclosed
EP-0626994-A4 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES. CHEVRON RES (US) 1995-08-23 EP disclosed
WO-1995018197-A1 MANNICH CONDENSATION PRODUCTS OF POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME CHEVRON CHEMICAL COMPANY (US) 1995-07-06 WO disclosed
US-5427591-A Detergent fuel additives, antideposit agents CHEVRON CHEMICAL COMPANY (US) 1995-06-27 US disclosed
EP-0629232-A1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES CHEVRON CHEMICAL COMPANY (US) 1994-12-21 EP disclosed
EP-0626994-A1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES CHEVRON CHEMICAL COMPANY (US) 1994-12-07 EP disclosed
US-5366519-A Antideposit agents for fuels CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1994-11-22 US disclosed
WO-1994014930-A1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1994-07-07 WO disclosed
WO-1994014928-A1 FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056575-A1 Anesthetic Compounds OPRL1, OPRM1, CYP3A5 FFAR4 1296/4885RXRA 1041/4885RXRB 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.